Detect Parkinson related brain changes
- Trial ID
- NCT06098612
- Official Title
- PET Imaging Evaluation of [11C]SY08
- Goal
- Detect Parkinson related brain changes
- Phase
- EARLY_PHASE1
- Status
- RECRUITING
- Sponsor
- Massachusetts General Hospital
- Study Type
- INTERVENTIONAL
- Enrollment
- 40 participants
- Conditions
- Parkinson's Disease, Multiple System Atrophy, Dementia With Lewy Bodies, Healthy Controls
- Interventions
- C11-SY08
Plain-Language Summary
The goal is to find out whether a new PET tracer called [11C]SY08 can reliably highlight disease-related brain changes in people with Parkinson's disease, multiple system atrophy, or dementia with Lewy bodies, compared with healthy volunteers. Participants get a single PET/MRI session after injection of the radiolabeled tracer, which is designed to bind to the pathological brain target so researchers can map where and how much signal appears; it is an imaging agent, not a treatment, and it does not change existing medications, so most people must be on stable meds for at least 30 days. The trial is looking for English-speaking adults age 50 to 80, including PD patients at Hoehn and Yahr stages I to IV, people with MSA or probable DLB with mild dementia, and healthy controls, and excludes those with major medical or psychiatric conditions, MRI or PET safety risks, or other listed contraindications.
Locations
- MGH, Charlestown, Massachusetts, United States
Frequently Asked Questions
- What is this trial testing?
- This trial is studying C11-SY08. The goal is to find out whether a new PET tracer called [11C]SY08 can reliably highlight disease-related brain changes in people with Parkinson's disease, multiple system atrophy, or dementia with Lewy bodies, compared with healthy volunteers. Participants get a single PET/MRI session after injection of the radiolabeled tracer, which is designed to bind to the pathological brain target so researchers can map where and how much signal appears; it is an imaging agent, not a treatment, and it does not change existing medications, so most people must be on stable meds for at least 30 days. The trial is looking for English-speaking adults age 50 to 80, including PD patients at Hoehn and Yahr stages I to IV, people with MSA or probable DLB with mild dementia, and healthy controls, and excludes those with major medical or psychiatric conditions, MRI or PET safety risks, or other listed contraindications.
- Who can participate?
- Participants must be between 50 Years and 80 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This Phase 1 trial is estimated to last approximately 2 years and 6 months.